BioData appoints Steve Yemm CEO


Steve Yemm has been appointed as the new CEO of BioData, replacing Nils Drache who will continue to be involved as a member of the company board.

Steve Yemm has been BioData’s VP of Sales for the last 2 years. During this time the company has successfully transitioned from a business-to-consumer model for purchase by single users, to one that delivers SaaS software solutions for institutions and companies in the life sciences.

BioData´s flagship product Labguru is a secure, web-based Electronic Lab Notebook (ELN), which records and manages laboratory data and inventory, helping labs to run more efficiently.

With two decades of experience in the scientific data management industry Steve brings an impressive sales and management record to BioData.

A chemist by training, he has led field based organisations for CambridgeSoft and IDBS, worked on global account strategy for Symyx Technologies and established the European and Asia-Pacific business of Core Informatics.

Throughout his career he has worked with clients across the world to successfully tackle informatics challenges and increase laboratory productivity.

“I am very pleased that Steve has accepted the role as CEO of BioData,” said Nils Drache.

“This move ensures continuity for the business as Steve knows both the company and the Labguru ELN product in detail. I look forward to seeing BioData’s strong management team continue to grow the business, enhanced by Steve’s broad experience and extensive track record.”

With Labguru, scientists can design experiments and workflows, capture structured and unstructured data, manage projects and share their work.

Customisable experiment templates, integration of protocols, SOPs and other cutting-edge features help to increase data quality, streamline workflows and reduce costs.

Sign up for your free email newsletter

Steve Yemm said: "I am delighted to be appointed as the CEO at BioData at a time when we are rapidly building our global presence as a result of wide and mainstream industry adoption of our technologies in the life sciences and adjacent science based industries."